# **Special Issue**

## Radiation Therapy for Modern Management of Bone Metastases

### Message from the Guest Editor

Bone metastases (BM) frequently occur during malignant disease. The incidence of BM is expected to rise in the future due to an increase in the survival rates of patients with cancer. Radiotherapy (RT) is a crucial part of the management of BM. RT can efficiently relieve pain and improve the quality of life of patients, thus forming a crucial part of palliative care in general. Moreover, recent insights suggest a clear effect on the improvement of the disease and overall survival by locally controlling single metastases, along with the administration of systemic therapies (thus including the ablative approach aiming for local control of BM) in oligometastatic settings. Finally, RT can play a role in improving the systemic effect of immune oncological therapy by the local treatment of lesions, including BM. The clinical indications, the prescriptive optimal dose for each clinical sub-setting and different aim, the target delineations and many other factors are still unclear, which makes investigating these issues an urgent challenge for modern oncologists and radiation oncologists in particular. Our Special Issue will deal these issues in this research field.

### **Guest Editor**

Dr. Francesco Cellini

Dipartimento di Diagnostica per Immagini, Radioterapia Oncologica ed Ematologia, Fondazione Policlinico Universitario "A. Gemelli" IRCCS, 00168 Roma, Italy

### Deadline for manuscript submissions

closed (30 November 2024)



### Cancers

an Open Access Journal by MDPI

Impact Factor 4.4
CiteScore 8.8
Indexed in PubMed



mdpi.com/si/167318

Cancers
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
cancers@mdpi.com

mdpi.com/journal/ cancers





## **Cancers**

an Open Access Journal by MDPI

Impact Factor 4.4 CiteScore 8.8 Indexed in PubMed



### **About the Journal**

### Message from the Editor-in-Chief

Cancers is an international online journal addressing both clinical and basic science issues related to cancer research. The journal is publishing in Open Access format, which will certainly evolve to ensure that the journal takes full advantage of the rapidly changing world of information and knowledge dissemination. It publishes high-quality clinical, translational, and basic science research on cancer prevention, initiation, progression, and treatment, as well as other related topics, particularly to capture the most seminal studies in the rapidly growing area of immunology, immunotherapy, and tumor microenvironment.

#### Editor-in-Chief

Prof. Dr. Samuel C. Mok.

Department of Gynecologic Oncology and Reproductive Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA

#### **Author Benefits**

### **Open Access:**

free for readers, with article processing charges (APC) paid by authors or their institutions.

### **High Visibility:**

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

#### Journal Rank:

JCR - Q2 (Oncology) / CiteScore - Q1 (Oncology)

